PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…
Search results for: secukinumab
Data Collection Drives Evaluation of Psoriasis Treatments
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
Drug Interactions for Trimethoprim/ Sulfamethoxazole Come to Light
Plus, updates on buprenorphine, diclofenac sodium, secukinumab and other rheumatology drug news, safety information
2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
Clinical manifestations, approaches to diagnosis, treatment
The ACR/ARHP Annual Meeting: Rheumatoid Arthritis Raises Mortality Risk in Women
Data from Nurses’ Health Study, other clinical trials point to higher risk of respiratory, cardiovascular disease death in women with RA
Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
EULAR 2013: Researchers Expand Targets for PsA, OA Therapy
Experts discuss insights in the pathogenesis of psoriatic arthritis and the role of subchondral bone in osteoarthritis
Drug Updates
Information on new approvals and medication safety.
- « Previous Page
- 1
- …
- 8
- 9
- 10